Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | unknown | PO / MO |
The patient took first dose of Vivotif with food; Case reference number US-BN-2025-000394 is a spontaneous case initially received from nurse via Communication (reference number: USBAV25-0642) on 20-Mar-2025 and concerns a 75-year-old, female patient. The patient's medical history and concomitant medication details were not provided. On 20-Mar-2025, the patient took the first dose of Vivotif with food (batch number: unknown), orally, at dose of one capsule, for indication typhoid fever immunization (explicitly coded as 'product administration error'). At the time of the initial report, it was unknown if the patient experienced any of adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A 75-year-old, female patient took the first dose of Vivotif with food, orally, at dose of one capsule, for indication typhoid fever immunization which is considered as product administration error. Product administration error is considered listed per company convention. At this point, it was unknown if the patient experienced any of adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 75-year-old, female patient took the first dose of Vivotif with food, orally, at dose of one capsule, for indication typhoid fever immunization which is considered as product administration error. Product administration error is considered listed per company convention. At this point, it was unknown if the patient experienced any of adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: NONE